4.6 Review

Neonatal Fc Receptor: From Immunity to Therapeutics

Journal

JOURNAL OF CLINICAL IMMUNOLOGY
Volume 30, Issue 6, Pages 777-789

Publisher

SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10875-010-9468-4

Keywords

FcRn; Fcgrt; Brambell; IgG; Fc; albumin; transcytosis; transport; recycling

Categories

Funding

  1. National Institute of Health [DK071798, DK053056, DK034854]
  2. American Liver Foundation
  3. Crohn's and Colitis Foundation

Ask authors/readers for more resources

The neonatal Fc receptor (FcRn), also known as the Brambell receptor and encoded by Fcgrt, is a MHC class I like molecule that functions to protect IgG and albumin from catabolism, mediates transport of IgG across epithelial cells, and is involved in antigen presentation by professional antigen presenting cells. Its function is evident in early life in the transport of IgG from mother to fetus and neonate for passive immunity and later in the development of adaptive immunity and other functions throughout life. The unique ability of this receptor to prolong the half-life of IgG and albumin has guided engineering of novel therapeutics. Here, we aim to summarize the basic understanding of FcRn biology, its functions in various organs, and the therapeutic design of antibody- and albumin-based therapeutics in light of their interactions with FcRn.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available